The group is preparing the sale of the dermatology division. Bloomberg's indiscretion causes the stock to slide on the Stock Exchange
(Teleborsa) – Bayer is traveling on several fronts between sales and acquisitions.
After having relaunched the offer on Monsanto, Bayer is reportedly considering the sale of its dermatological division. A non-core business to focus on the glyphosate group acquisition.
If the deal goes through, it would bring more than $1,1 billion into Bayer's coffers. The indiscretion reported by Bloomberg causes the stock to slide on the stock exchange, which falls by 1,25%.
FIRSTonline is an independent web journal of economics, finance and stock exchange published by AL Iniziative Editoriali Srl with registered office in Rome, founded and controlled by Ernesto Auci e Franco Locatelli and owned by two minority shareholders (Alessandro Pavesi and Laura Rovizzi). The portal and its applications are created in daily life by two agile editorial offices, one in Milan and one in Milan Roma, and by an innovative and effective team of innovation and web managers.
